cheap iphone Cases Sign in / Join NowParatek Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Remains on Track for Commercial Launch by First Quarter 2019Thu March 1, 2018 7:00 AMGlobeNewswireAbout: PRTKCompleted submission of NDAs for oral and intravenous omadacycline for the treatment of pneumonia and skin infectionsExpanded medical affairs and payer account management teams in readiness for discussions with formulary committeesAnnounced FDA acceptance of Allergan's NDA for SEYSARA (sarecycline)BOSTON, March 01, 2018 (GLOBE NEWSWIRE) Paratek Pharmaceuticals, Inc.
(PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today reported financial results and provided an update on financial, clinical, and regulatory filing activities for the quarter and full year ended December 31, 2017."We had a strong finish to the year as we initiated our Phase 2 program in urinary tract infections and, importantly, we recently announced the completion of the rolling NDA submissions for omadacycline," said Michael Bigham, Chairman and Chief Executive Officer, Paratek.
Food and Drug Administration (FDA) on February 2, 2018 for the once daily oral and intravenous formulations of omadacycline for the treatment of community acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI)Initiated the first of two Phase 2 studies of omadacycline in urinary tract infections (UTI)Announced FDA acceptance of Allergan's NDA for SeysaraRaised $50.0 million through a registered underwritten public offering of common stockFDA acceptance of omadacycline NDAs anticipated in April 2018Formulary discussions with payers to begin post FDA acceptance of NDA filingPresentation of clinical and microbiological data at the upcoming European Congress of Clinical Microbiology and Infectious Disease, including nine posters and one oral presentation of the OASIS 2 study of oral only omadacycline in ABSSSIEuropean pre submission meetings planned for the second quarter of 2018Fourth Quarter and Full Year 2017 Financial ResultsFor the fourth quarter of 2017, Paratek reported a net loss of $21.9 million, or ($0.78) per share, compared to a net loss of $26.5 million, or ($1.16) per share, for the same period in 2016.

cheap iphone Cases

iphone 7 plus case I was there, and would like the true story to be told. Rob got Narla when she was a baby, not 5 months old as was inaccurately reported. She was no bigger than a puppy, still had her baby fuzz and spots and was still being bottle fed. That makes for a very wealthy organization. A wealthy organization has the funds to sue everyone in their path into submission. It a pretty impressive monster, combining the most abusive aspects of religion with the most unethical aspects of business.
iphone 7 plus case